Eli Lilly & Co. is asking people who took copies of its blockbuster weight loss drug to give the company access to their ...

Shares of Eli Lilly & Co. LLY advanced 1.11% to $915.04 Thursday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index SPX rising 1.70% to 5,713.64 and ...

New educational tool will help companies assess how well their health and well-being programs support their workforce’s brain ...

One of the world’s largest drug manufacturers is suing a small east metro wellness center over the way it marketed and sold a ...

They plan to fund the water main extension with forgivable loans from a state drinking water fund fed by federal dollars.

A good example is the healthcare sector. It has been out of favour for a few years and valuations are attractive. Yet the fundamentals continue to be sound, if not improving, and concerns are ...

Natural supplements have “very mild effects” on weight loss based on what Dr. Ali has seen. There is some data to suggest ...

Eli Lilly’s stock has climbed almost 60% this year and trades for more than $900. The pharma giant also has seen soaring ...

Obesity-focused biotech BioAge Labs said on Wednesday it was seeking a valuation of as much as $587 million in its initial ...

according to the company’s website. Most U.S. patients are covered by health insurance and would likely pay less for the drugs. Novo and rival Eli Lilly, which makes the weight loss drug Zepbound, ...

There is soaring demand for weight-loss drugs in the GLP-1 class, and the company will now sell it to certain professions for ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch Automation brings you the latest, most pertinent content at record speed and with ...